Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$2.35B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$169M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Davis George Eric | Feb 26, 2026 | Sell | 26,061 | $61.36 | $1.6M |
| Friberg Gregory R | Feb 26, 2026 | Sell | 6,326 | $60.3758 | $380,000 |
| Burkhart Erin | May 20, 2025 | Sell | 1,786 | $59.31 | $110,000 |
| Hubbard Cristin | May 2, 2025 | Sell | 273 | $64.92 | $18,000 |
| Burkhart Erin | Mar 19, 2025 | Sell | 1,295 | $71.52 | $93,000 |
| Guyer Charles Greg | Mar 6, 2025 | Sell | 7,034 | $71.276 | $500,000 |
| Burkhart Erin | Feb 24, 2025 | Sell | 1,344 | $68.38 | $92,000 |
| Guyer Charles Greg | Nov 12, 2024 | Sell | 5,278 | $66.3743 | $350,000 |
| Burkhart Erin | Aug 13, 2024 | Sell | 714 | $90 | $64,000 |
| Mueller Brian | May 30, 2024 | Sell | 5,000 | $75.19 | $380,000 |
| Davis George Eric | May 28, 2024 | Sell | 38,071 | $74.455 | $2.8M |
| Davis George Eric | May 28, 2024 | Sell | 2,779 | $75.288 | $210,000 |
| BIENAIME JEAN JACQUES | May 10, 2024 | Sell | 20,000 | $81.14 | $1.6M |
| Davis George Eric | May 2, 2024 | Sell | 1,850 | $85.01 | $160,000 |
| Ajer Jeffrey Robert | May 2, 2024 | Sell | 5,000 | $82.91 | $410,000 |
| BIENAIME JEAN JACQUES | Apr 12, 2024 | Sell | 20,000 | $91.26 | $1.8M |
| Burkhart Erin | Apr 10, 2024 | Sell | 2,286 | $90 | $210,000 |
| Davis George Eric | Mar 28, 2024 | Sell | 24,602 | $88.34 | $2.2M |
FAQ - Insider Transactions
The most recent insider transaction for Biomarin Pharmaceutical was conducted by Davis George Eric, who sold 26,061 shares on February 26, 2026 at a price of $61.36 per share.
Davis George Eric has sold the most BMRN stock in the last 2 years, with a total value of $7M.
The total value of insider transactions for Biomarin Pharmaceutical in the last 2 years is negative, amounting to -$13M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Biomarin Pharmaceutical have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
